Obviousness in View of Canceled Claims
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
BECTON, DICKINSON AND COMPANY v. BAXTER CORPORATION ENGLEWOOD
Before Prost, Clevenger, and Dyk. Appeal from the Patent Trial and Appeal Board.
Summary: A patent that has issued and subsequently been canceled may be cited as a reference in an IPR.
Becton Dickinson (BD) requested Inter Partes Review of Baxter’s patent directed to enabling a remote pharmacist to manage a technician’s preparation of drugs. The PTAB found the challenged claims not invalid because the limitations of requiring “verification” from the pharmacist at each step before proceeding, and enabling “highlighting” of each step to prompt the display of more information, were not taught or rendered obvious by the cited prior art.
The Federal Circuit held that the PTAB’s findings were not supported by substantial evidence and reversed. The Federal Circuit also addressed Baxter’s alternative ground raised on appeal – that the U.S. patent asserted by BD was not prior art under 35 U.S.C. § 102(e)(2) (pre-AIA) because all claims of that patent were canceled in an IPR. The Federal Circuit rejected that argument and noted that the statute requires only that a grant has occurred, not that the patent is currently valid.
Editor: Paul Stewart
Written by: Hans L. Mayer
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…